FIELD: chemistry.
SUBSTANCE: group of inventions relates to a composition of fatty acids and use thereof for preparing a medicinal drug. Invention discloses: a composition for increasing plasma and/or serum eicosapentaenoic acid (EPA) in a subject with initial triglyceride levels from 200 to 500 mg/dl and EPA not more than 50 mcg/ml, going through constant statin therapy, composition contains at least 96 wt% ethyl eicosapentaenoate, from 0.2 to 0.5 wt% ethyl octadecatetraenoate, from 0.05 to 0.25 wt% ethyl nonaecapentaenoate, from 0.2 to 0.45 wt% ethyl arachidonate, from 0.3 to 0.5 wt% ethyl eicosatetraenoate, from 0.05–0.32 wt% ethyl heneicosapentaenoate and not more than 0.05 % ethyl docosahexaenoic acid (ethyl-DHA), if it is present, and using said composition for preparing a drug for increasing levels of EPA in plasma (serum) of said subject by at least 200 % in comparison with initial level.
EFFECT: technical result is administration of 1 capsule of 2 g AMR101 a day in said group of patients increased levels of EPA after 6 weeks by 4 times; dose of AMR101 of 4 g a day after 6 weeks increased EPA levels by 5 times.
7 cl, 2 dwg, 8 tbl, 4 ex
